Foghorn Therapeutics Inc stock is traded at $1.91, with a volume of 1,008,779. It is down -9.29% in the last 24 hours and down -4.75% over the past month. Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Previous Close:
$2.10
Open:
$2.10
24h Volume:
1,008,779
Relative Volume:
1.59
Market Cap:
$113.13M
Revenue:
$30.91M
Net Income/Loss:
-$74.28M
P/E Ratio:
-
EPS:
-$1.22
Net Cash Flow:
-$86.15M
1W Performance:
-8.85%
1M Performance:
-4.75%
6M Performance:
-58.94%
1Y Performance:
-52.38%
1-Day Range:
$1.80$2.10
1-Week Range:
$1.80$2.28
52-Week Range:
$1.79$7.61
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-586-3100Address
500 TECHNOLOGY SQUARE, CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS